An open-label multi-center, randomized Phase II trial of the anti-PD-1 monoclonal antibody nivolumab (Opdivo) versus nivolumab plus bavituximab in patients with previously treated locally advanced or metastatic NSCLC
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2015
At a glance
- Drugs Bavituximab (Primary) ; Nivolumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Sep 2015 Planned initiation date changed from 1 Jul 2015 to 1 Dec 2015, based on a Peregrine Pharmaceuticals media release.
- 03 Jun 2015 New trial record
- 01 Jun 2015 According to a Peregrine media release, the company expects to initiate this trial in the second half of 2015.